Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | TNFRSF1A | P19438 | 14/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093001 | 0.88 | RAB9A (0.50) | HDAC1TNFRSF1AMEN1ALDH1A1KMT2A | |
| SCHEMBL6092244 | 0.88 | TNFRSF1A (0.44) | HDAC1TNFRSF1AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6092294 | 0.86 | TNFRSF1A (0.45) | HDAC1TNFRSF1AALDH1A1KMT2AHDAC2 | |
| SCHEMBL6092061 | 0.84 | TNFRSF1A (0.51) | HDAC1TNFRSF1AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6093064 | 0.83 | TNFRSF1A (0.52) | TNFRSF1AKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6040654 | 0.83 | TNFRSF1A (0.52) | TNFRSF1AKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL6091657 | 0.83 | TNFRSF1A (0.46) | HDAC1TNFRSF1AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6094667 | 0.82 | HDAC1 (0.47) | HDAC1TNFRSF1AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6092896 | 0.82 | TNFRSF1A (0.52) | HDAC1TNFRSF1AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6092892 | 0.82 | TNFRSF1A (0.53) | HDAC1TNFRSF1AKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | claimed |
| WO-2006004903-A2 | 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ATHEROGENICS, INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | HDAC1 1097/4885TNFRSF1A 4880/4885KDM4E 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.